Early and Sustained Clinical Benefits of Benralizumab in Severe Eosinophilic Asthma: Findings from the ORBE II Study. [PDF]
Ausín P+8 more
europepmc +1 more source
Correspondence to 'Interleukin-5 as a Pleiotropic Cytokine Orchestrating Airway Type 2 Inflammation: Effects on and Beyond Eosinophils'. [PDF]
McCrae C, Jison ML, Menzies-Gow A.
europepmc +1 more source
Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. [PDF]
Shiomi M+5 more
europepmc +1 more source
Benralizumab as initial treatment for chronic eosinophilic pneumonia
Mikio Toyoshima+3 more
openaire +3 more sources
Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO study. [PDF]
Altrichter S+11 more
europepmc +1 more source
Insights and considerations in the use of biologics for managing eosinophilic exacerbations in asthma and chronic obstructive pulmonary disease. [PDF]
Kim SH, Kim Y, Moon JY, Min KH, Lee H.
europepmc +1 more source
A case of paradoxical eosinophilic fasciitis in a patient on benralizumab
Michael J. Woodbury, BS+2 more
openaire +2 more sources
Benralizumab and the integrated management of co-morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps. [PDF]
Mullol J+4 more
europepmc +1 more source
Out of Breath, out of Options: Benralizumab as a Last Hope in ICU-Treated Near-Fatal Eosinophilic Asthma: A Case Series. [PDF]
Conemans L+4 more
europepmc +1 more source